Immunic plans to go public via Vital Therapies

Vital Therapies Inc. (NASDAQ:VTL) will acquire all outstanding shares of Immunic AG (Martinsried, Germany). The resulting company, which will retain Immunic's name and trade on NASDAQ, will develop Immunic’s pipeline, including IMU-838, a molecule inhibitor of dihydroorotate dehydrogenase (DHODH) in Phase II to treat ulcerative colitis.

At closing, Vital will receive €26 million ($29.8 million) in financing from Life Sciences Partners, Omega Funds, Fund+, LifeCare Partners, Bayern Kapital, High-Tech Gründerfonds and IBG...